Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., “Veloxis”) before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company (“Cornerstone”), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. in 2014. Mr. Collard also served as Cornerstone’s Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from 2004 to 2008. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. From 2002 to 2003, Mr. Collard served as Vice President of Sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Collard currently serves on the board of directors of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing therapies to treat substance use disorders and drug overdoses, since October 2018 and as Chairman, since January 2021. Mr. Collard has also served on the board of directors of TerrAscend Corp., a North American cannabis operator based in Mississauga, Canada, since December 2018. Mr. Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May 2020 to July 2022. Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University).
What is Craig A. Collard's net worth?
The estimated net worth of Craig A. Collard is at least $244.31 thousand as of November 16th, 2023. Mr. Collard owns 186,496 shares of Heron Therapeutics stock worth more than $244,310 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Collard may own. Learn More about Craig A. Collard's net worth.
How old is Craig A. Collard?
How do I contact Craig A. Collard?
Has Craig A. Collard been buying or selling shares of Heron Therapeutics?
Craig A. Collard has not been actively trading shares of Heron Therapeutics during the past quarter. Most recently, on Thursday, November 16th, Craig A. Collard bought 150,000 shares of Heron Therapeutics stock. The stock was acquired at an average cost of $0.92 per share, with a total value of $138,000.00. Following the completion of the transaction, the chief executive officer now directly owns 186,496 shares of the company's stock, valued at $171,576.32. Learn More on Craig A. Collard's trading history.
Who are Heron Therapeutics' active insiders?
Are insiders buying or selling shares of Heron Therapeutics?
In the last year, Heron Therapeutics insiders bought shares 2 times. They purchased a total of 4,153,771 shares worth more than $6,230,656.50. The most recent insider tranaction occured on August, 8th when Director Adam Morgan bought 1,766,546 shares worth more than $2,649,819.00. Insiders at Heron Therapeutics own 5.9% of the company.
Learn More about insider trades at Heron Therapeutics. Information on this page was last updated on 8/8/2025.
